ROIV · Roivant Sciences Ltd.

$36.20 -0.08 (-0.22%) At close · Aug 14

Market Cap

$26.15B

722.32M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Frank Torti	President and Vant Chair	$725,000	$8,428,000	$109,338,796	—	—	$4,808,770	$123,300,566
Eric Venker	President and Immunovant CEO	$75,000	$1,899,316	$2,261,908	—	—	$20,163,986	$24,400,210
Richard Pulik	Chief Financial Officer	$450,883	$1,277,130	$1,420,299	$1,018,269	—	$24,021	$4,190,602
Matthew Gline	Chief Executive Officer	$725,000	$2,359,250	—	—	—	$11,940	$3,096,190
Mayukh Sukhatme	President and Chief Investment Officer	$550,000	$704,000	—	—	—	$22,655	$1,276,655

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mayukh Sukhatme	President and Chief Investment Officer	$550,000	$81,069,750	$170,217,983	—	—	$21,032	$251,858,764
Matthew Gline	Chief Executive Officer	$725,000	$4,978,875	$157,577,851	—	—	$12,018	$163,293,744
Eric Venker	President and Immunovant CEO	$600,208	$6,038,175	$2,203,200	$2,933,103	—	$32,736	$11,807,422
Rakhi Kumar	Former Chief Accounting Officer	$370,156	$1,650,328	$412,382	$1,862,828	—	$398,244	$4,693,938
Richard Pulik	Chief Financial Officer	$437,750	$1,113,674	$410,061	$2,163,910	—	$1,755	$4,127,151
Jennifer Humes	Chief Accounting Officer	$41,897	$281,450	$1,231,437	$826,878	—	$1,293	$2,382,956

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Richard Pulik	Chief Financial Officer	$425,000	$1,846,250	$587,048	$2,273,748	—	$17,388	$5,149,434
Rakhi Kumar	Former Chief Accounting Officer	$375,000	$1,657,828	$587,048	$1,698,113	—	$13,170	$4,331,159
Matthew Gline	Chief Executive Officer	$725,000	—	—	—	—	$13,189	$738,189
Eric Venker	President and Immunovant CEO	$570,000	—	—	—	—	$62,420	$632,420
Mayukh Sukhatme	President and Chief Investment Officer	$550,000	—	—	—	—	$24,560	$574,560

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Matthew Gline	Chief Executive Officer	$725,000	$1,036,750	—	$47,206,737	—	$10,339	$48,978,825
Mayukh Sukhatme	President and Chief Investment Officer	$450,000	$1,243,500	—	$47,206,737	—	$25,346	$48,925,582
Eric Venker	President and Immunovant CEO	$569,806	$637,630	—	$47,206,737	—	$73,794	$48,487,966

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Matthew Gline	Chief Executive Officer	$725,000	$710,500	$9,500,630	$19,513,106	—	$10,795	$30,460,032
Eric Venker	M.D., Pharm.D. President and Chief Operating Officer	$620,000	$279,493	$9,500,630	$13,826,290	—	$81,888	$24,308,300
Mayukh Sukhatme	President and Chief Investment Officer	$450,000	$441,000	—	$16,578,239	—	$19,186	$17,488,425

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Eric Venker	M.D., Pharm.D. President and Chief Operating Officer	$275,000	$455,000	$5,734,500	$3,748,500	—	$83,550	$10,296,550
Matthew Gline	Chief Executive Officer	$350,000	$455,000	—	$7,497,000	—	$8,550	$8,310,550

Executive changes

Person	Role	Change	Effective	Filed
Jennifer Humes	Principal Accounting Officer of Roivant Sciences Ltd. and Chief Accounting Officer of Roivant Sciences, Inc.	Appointed	2025-02-20	2025-02-21
Hiroshi Nomura	Class III director	Resigned	2023-08-31	2023-08-04
Meghan M. FitzGerald, DrPH	Class II director	Appointed	2023-03-13	2023-03-16
Vivek Ramaswamy	Class II director	Resigned	2023-02-20	2023-02-21
Andrew Lo	Class II director	Resigned	2022-11-17	2022-11-23
Hiroshi Nomura	Class III director	Appointed	2022-09-16	2022-09-21
Masayo Tada	director	Resigned	2022-09-16	2022-09-21
Melissa Epperly	Class I director	Appointed	2022-06-29	2022-06-28

Key facts CIK 1635088 CUSIP G76279101 13F (30d) 472 filings 454 filers Visit website Investor relations